{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:31:13Z","timestamp":1791855073901,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05323-3","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:23:01Z","timestamp":1765470181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment strategies and innovation for recurrent high-grade glioma"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-7119","authenticated-orcid":false,"given":"Jan","family":"Drappatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-6696","authenticated-orcid":false,"given":"Megan","family":"Mantica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"5323_CR1","first-page":"1210","volume":"41","author":"RM Young","year":"2023","unstructured":"Young RM, Gupta S, Snyder J et al. (2023) Pseudoprogression and radionecrosis in glioblastoma: imaging challenges. J Clin Oncol 41:1210\u20131218","journal-title":"J Clin Oncol"},{"key":"5323_CR2","first-page":"1185","volume":"26","author":"DR Johnson","year":"2024","unstructured":"Johnson DR, Jenkins RB, Kosel ML et al. (2024) Contemporary outcomes for recurrent glioblastoma: US real-world data. Neuro Oncol 26:1185\u20131194","journal-title":"Neuro Oncol"},{"key":"5323_CR3","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/neuonc\/noaf201.0549","volume":"27","author":"TF Cloughesy","year":"2025","unstructured":"Cloughesy TF, Weller M, van den Bent MJ et al. (2025) Novel endpoints and trial design in glioblastoma. Neuro Oncol 27:1900\u20131910","journal-title":"Neuro Oncol"},{"key":"5323_CR4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller M, Cloughesy T, Perry JR et al. (2014) EORTC 26101: lomustine \u00b1 bevacizumab in recurrent glioblastoma. Lancet Oncol 15:1100\u20131109","journal-title":"The Lancet Oncol"},{"key":"5323_CR5","first-page":"322","volume":"379","author":"W Wick","year":"2018","unstructured":"Wick W, Gorlia T, Bendszus M et al. (2018) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 379:322\u2013333","journal-title":"N Engl J Med"},{"key":"5323_CR6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2023.41.16_suppl.1002","volume":"41","author":"JR Perry","year":"2023","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ et al. (2023) Temozolomide rechallenge in MGMT-methylated glioma. J Clin Oncol 41:1002\u20131010","journal-title":"J Clin Oncol"},{"key":"5323_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AME et al. (2014) Single-agent bevacizumab or lomustine in recurrent glioblastoma: randomized phase II study. Lancet Oncol 15:943\u2013953","journal-title":"The Lancet Oncol"},{"key":"5323_CR8","doi-asserted-by":"crossref","first-page":"102189","DOI":"10.1016\/j.ctrv.2021.102189","volume":"97","author":"R Stupp","year":"2021","unstructured":"Stupp R, Wong ET, Kanner AA et al. (2021) Tumor treating fields in glioblastoma: clinical data and mechanisms. Cancer Treat Rev 97:102189","journal-title":"Cancer Treat Rev"},{"key":"5323_CR9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","volume":"20","author":"M Caccese","year":"2019","unstructured":"Caccese M, Lombardi G, Zagonel V et al. (2019) Regorafenib compared with lomustine in recurrent glioblastoma (REGOMA): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 20:1109\u20131119","journal-title":"The Lancet Oncol"},{"key":"5323_CR10","first-page":"1789","volume":"25","author":"PY Wen","year":"2023","unstructured":"Wen PY, Alexander BM, Drappatz J et al. (2023) GBM AGILE regorafenib arm results. Neuro Oncol 25:1789\u20131799","journal-title":"Neuro Oncol"},{"key":"5323_CR11","first-page":"222","volume":"26","author":"AB Lassman","year":"2024","unstructured":"Lassman AB, Wen PY, Aldape KD et al. (2024) GBM AGILE update and adaptive design. Neuro Oncol 26:222\u2013230","journal-title":"Neuro Oncol"},{"key":"5323_CR12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-19-1059","volume":"10","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L et al. (2020) Larotrectinib and entrectinib activity in NTRK fusion-positive glioma. Cancer Discov 10:568\u2013575","journal-title":"Cancer Discov"},{"key":"5323_CR13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/neuonc\/noae052","volume":"26","author":"TM Johanns","year":"2024","unstructured":"Johanns TM, Ferguson CJ, Grierson PM et al. (2024) Dabrafenib \u00b1 trametinib in BRAF-mutated glioblastoma: case series. Neuro Oncol 26:1025\u20131032","journal-title":"Neuro Oncol"},{"key":"5323_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Ellingson BM, Touat M et al. (2023) Vorasidenib in IDH-mutant grade 2 glioma. N Engl J Med 389:299\u2013310","journal-title":"N Engl J Med"},{"key":"5323_CR15","first-page":"450","volume":"14","author":"TF Cloughesy","year":"2024","unstructured":"Cloughesy TF, Cavenee WK, Mischel PS et al. (2024) EGFRvIII-targeted therapies in glioblastoma. Cancer Discov 14:450\u2013460","journal-title":"Cancer Discov"},{"key":"5323_CR16","first-page":"45","volume":"10","author":"US Food and Drug Administration","year":"2024","unstructured":"US Food and Drug Administration (2024) Tovorafenib (Ojemda) accelerated approval for pediatric low-grade glioma. FDA Drug Approvals 10:45\u201347","journal-title":"FDA Drug Approvals"},{"key":"5323_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M et al. (2022) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant high-grade and low-grade glioma (ROAR): an open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53\u201364","journal-title":"The Lancet Oncol"},{"key":"5323_CR18","first-page":"450","volume":"119","author":"WR Kennedy","year":"2024","unstructured":"Kennedy WR, Brown PD, Bahrami A et al. (2024) AZD1390 combined with radiotherapy: phase 0\/1b study. Int J Radiat Oncol Biol Phys 119:450\u2013459","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5323_CR19","first-page":"1123","volume":"14","author":"AACR Newsroom","year":"2024","unstructured":"AACR Newsroom (2024) AZD1390 with radiotherapy demonstrates early efficacy and safety. Cancer Discov 14:1123\u20131125","journal-title":"Cancer Discov"},{"key":"5323_CR20","first-page":"55","volume":"38","author":"R Conroy","year":"2024","unstructured":"Conroy R (2024) AZD1390 radiosensitization summary. Cancer Network 38:55\u201358","journal-title":"Cancer Network"},{"key":"5323_CR21","first-page":"55","volume":"168","author":"G Minniti","year":"2024","unstructured":"Minniti G, Scaringi C, Lanzetta G et al. (2024) Re-irradiation outcomes in recurrent glioblastoma: prospective cohorts. J Neurooncol 168:55\u201363","journal-title":"J Neurooncol"},{"key":"5323_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2020.38.15_suppl.6004","volume":"38","author":"MR Gilbert","year":"2020","unstructured":"Gilbert MR, Wang M, Aldape KD et al. (2020) Veliparib plus temozolomide in recurrent glioblastoma: phase II trial. J Clin Oncol 38:241\u2013250","journal-title":"J Clin Oncol"},{"key":"5323_CR23","first-page":"1120","volume":"25","author":"DA Reardon","year":"2023","unstructured":"Reardon DA, Brandes AA, Omuro A et al. (2023) PD-1 blockade combinations in recurrent glioblastoma. Neuro Oncol 25:1120\u20131128","journal-title":"Neuro Oncol"},{"key":"5323_CR24","first-page":"1800","volume":"30","author":"M Lim","year":"2024","unstructured":"Lim M, Li G, Vogelbaum MA et al. (2024) TIGIT and LAG-3 as emerging immunotherapy targets in glioblastoma. Clin Cancer Res 30:1800\u20131810","journal-title":"Clin Cancer Res"},{"key":"5323_CR25","first-page":"1520","volume":"24","author":"E Galanis","year":"2022","unstructured":"Galanis E, Uhm JH, Dietrich J et al. (2022) Viral therapy trials in recurrent glioblastoma: lessons learned. Neuro Oncol 24:1520\u20131528","journal-title":"Neuro Oncol"},{"key":"5323_CR26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41698-024-00570-5","volume":"8","author":"S Park","year":"2024","unstructured":"Park S, Lim M, Johnson DR et al. (2024) CAR T-cell therapy for adult brain tumors: progress and challenges. npj Precis Oncol 8:77","journal-title":"Npj Precis Oncol"},{"key":"5323_CR27","first-page":"233","volume":"52","author":"SL Bagley","year":"2025","unstructured":"Bagley SL, Chen R, Huang J et al. (2025) CAR T therapy in glioblastoma: safety, efficacy, and delivery. Semin Oncol 52:233\u2013244","journal-title":"Semin Oncol"},{"key":"5323_CR28","first-page":"88","volume":"11","author":"SV Belokon","year":"2025","unstructured":"Belokon SV, Yu Y, Zeng C et al. (2025) CAR T therapy for glioblastoma: a critical review. Hematol Cell Ther Transl 11:88\u201399","journal-title":"Hematol Cell Ther Transl"},{"key":"5323_CR29","first-page":"1050","volume":"19","author":"ecancer News","year":"2025","unstructured":"ecancer News (2025) ASCO 2025 dual-target CAR T-cell findings in glioblastoma. Ecancer 19:1050\u20131052","journal-title":"Ecancer"},{"key":"5323_CR30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/neuonc\/noae165.1220","volume":"26","author":"S Gholamin","year":"2024","unstructured":"Gholamin S, Majzner RG, Cheshier SH et al. (2024) Overcoming myeloid resistance to IL13R\u03b12 CAR T cells in glioblastoma. Neuro Oncol 26:1230\u20131238","journal-title":"Neuro Oncol"},{"key":"5323_CR31","first-page":"2015","volume":"27","author":"JJ Zhu","year":"2025","unstructured":"Zhu JJ, Heimberger AB, Youssef S et al. (2025) IL13R\u03b12 CAR T-cell therapy: updated clinical trial results. Neuro Oncol 27:2015\u20132022","journal-title":"Neuro Oncol"},{"key":"5323_CR32","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1200\/JCO-25-00250","volume":"43","author":"JO Blakeley","year":"2025","unstructured":"Blakeley JO, Colman H, Sulman EP et al. (2025) ASCO\u2013SNO rapid guideline update for adult diffuse gliomas. J Clin Oncol 43:2100\u20132110","journal-title":"J Clin Oncol"},{"key":"5323_CR33","first-page":"1500","volume":"27","author":"Society for Neuro-Oncology","year":"2025","unstructured":"Society for Neuro-Oncology (2025) SNO guideline endorsements. Neuro Oncol 27:1500\u20131505","journal-title":"Neuro Oncol"},{"key":"5323_CR34","first-page":"1345","volume":"27","author":"N Andratschke","year":"2025","unstructured":"Andratschke N, Guckenberger M, Niyazi M et al. (2025) Re-irradiation in glioblastoma: point\/counterpoint. Neuro Oncol 27:1345\u20131352","journal-title":"Neuro Oncol"},{"key":"5323_CR35","first-page":"210","volume":"14","author":"NCI Cancer Currents","year":"2024","unstructured":"NCI Cancer Currents (2024) Tovorafenib approval overview. Cancer Curr 14:210\u2013212","journal-title":"Cancer Curr"},{"key":"5323_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Chi AS, Batchelor TT et al. (2024) ONC201 (dordaviprone) in H3K27M diffuse midline glioma. J Clin Oncol 42:150\u2013158","journal-title":"J Clin Oncol"},{"key":"5323_CR37","first-page":"100","volume":"192","author":"D Di Carlo","year":"2025","unstructured":"Di Carlo D, Smith J, Patel A et al. (2025) Real-world dordaviprone outcomes in H3K27-altered diffuse midline glioma. Eur J Cancer 192:100\u2013110","journal-title":"Eur J Cancer"},{"key":"5323_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M et al. (2018) DNA methylation-based classification of central nervous system tumors. Nature 555:469\u2013474","journal-title":"Nature"},{"key":"5323_CR39","first-page":"1560","volume":"27","author":"BM Alexander","year":"2025","unstructured":"Alexander BM, Trister AD, Colman H et al. (2025) INSIGhT platform trial for newly diagnosed GBM. Neuro Oncol 27:1560\u20131568","journal-title":"Neuro Oncol"},{"key":"5323_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J et al. (2019) Personalized neoantigen vaccine in glioblastoma. Nature 565:234\u2013239","journal-title":"Nature"},{"key":"5323_CR41","first-page":"120","volume":"141","author":"T Mainprize","year":"2024","unstructured":"Mainprize T, Lipsman N, Schwartz ML et al. (2024) Focused ultrasound blood\u2013brain barrier opening in high-grade glioma. J Neurosurg 141:120\u2013128","journal-title":"J Neurosurg"},{"key":"5323_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Tran DD et al. (2023) Dendritic cell vaccine DCVax-L for glioblastoma: final trial analysis. JAMA Oncol 9:112\u2013121","journal-title":"JAMA Oncol"},{"key":"5323_CR43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE et al. (2018) Recurrent glioblastoma treated with oncolytic poliovirus PVSRIPO. N Engl J Med 379:1507\u20131518","journal-title":"N Engl J Med"},{"key":"5323_CR44","first-page":"250","volume":"30","author":"TR Hodges","year":"2024","unstructured":"Hodges TR, Ott M, Fangusaro J et al. (2024) Immune correlates of response in glioblastoma immunotherapy trials. Nat Med 30:250\u2013260","journal-title":"Nat Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05323-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05323-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05323-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:02:49Z","timestamp":1767704569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05323-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5323"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05323-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors. Ethical approval is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Dr. Jan Drappatz reports research support from Servier, AstraZeneca, and Novartis; and stockholder\/equity interests in Pfizer and Gilead. Dr. Megan Mantica reports no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}